JemP的个人主页 - 老虎社区

JemP

JemP

暂无个人介绍

IP属地：未知

4关注

4粉丝

0主题

0勋章

2021-12-29

Yes

抱歉，原内容已删除

2021-12-26

Yes

Tech Roundup: Micron and 2022 predictions lead Christmas-shortened week's action

2021-12-25

Good

3 Best Buffett Stocks to Buy for the Long Haul

2021-12-18

Thanks for info

1 Surefire Growth Stock to Buy and Hold

2021-12-18

Good

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3579236690659078,"uuid":"3579236690659078","gmtCreate":1618711550336,"gmtModify":1636681364257,"name":"JemP","pinyin":"jemp","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":4,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696723093,"gmtCreate":1640774600324,"gmtModify":1640774600489,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696723093","repostId":"1198370121","repostType":4,"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698487888,"gmtCreate":1640494482107,"gmtModify":1640494482185,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698487888","repostId":"1132092278","repostType":4,"repost":{"id":"1132092278","pubTimestamp":1640480606,"share":"https://www.laohu8.com/m/news/1132092278?lang=&edition=full","pubTime":"2021-12-26 09:03","market":"us","language":"en","title":"Tech Roundup: Micron and 2022 predictions lead Christmas-shortened week's action","url":"https://stock-news.laohu8.com/highlight/detail?id=1132092278","media":"Seeking Alpha","summary":"It may have been a short week for Wall Street due to stock markets being closed on Friday because of","content":"<ul>\n <li>It may have been a short week for Wall Street due to stock markets being closed on Friday because of&nbsp;the Christmas holiday, but that didn't keep a handful of tech companies from remaining active during what is normally a relatively quiet time of the year.</li>\n <li>Micron Technology(NASDAQ:MU)started things off when, on Monday, it reported strong quarterly results, and gave a business outlook that suggested it is taking steps to alleviate supply chain issues&nbsp;that have impacted the chip sector this year.</li>\n <li>Along with its upbeat forecast, Micron (MU) got high marks from Rosenblatt Securities analyst Hans Mosesmann, who named Micron (MU)one of his top semiconductor picks for 2022. By the time U.S. stock markets closed Thursday, Micron (MU) shares had climbed 13% for the week.</li>\n <li>Oracle(NYSE:ORCL)appeared to be going back to its old-school big-dealing ways when&nbsp;it said it would pay $28.3 billion in cash&nbsp;to buy healthcare technology company Cerner(NASDAQ:CERN)in what stands to be Oracle's (ORCL) largest-ever acquisition.</li>\n <li>Chinese tech stocks had their usual bit of drama, as Alibaba(NYSE:BABA)shares bounced up and down after&nbsp;Atlantic Equities downgraded the Internet giant, and JD.com(NASDAQ:JD)slumped at the end of the week after Tencent Holdings(OTCPK:TCEHY)said it would divest most of its&nbsp;holdings in the Chinese e-commerce and retail company.</li>\n <li>Analysts spent much of the week leading up to Christmas by getting in their takes on what to expect from various tech sectors next year.</li>\n <li>UBS analyst Timothy Arcuri said Nvidia(NASDAQ:NVDA), Micron (MU) and Marvell(NASDAQ:MRVL)were his top selections for&nbsp;investors looking at semiconductor stocks in 2022, while Citi analyst Jim Suva gave five examples of why Apple(NASDAQ:AAPL)shares should continue to rise next yearand lift the company's market value past $3 trillion.</li>\n <li>Meanwhile, MKM Partners managing director pointed out10 examples of \"Black Swan\" eventsthat, while not likely to happen, would have huge impacts on the Internet sector if they did.</li>\n <li>You know all those kids and everyone else that using and watching videos on TikTok? Well, they have all helped TikTok to surpass Google(NASDAQ:GOOG)as&nbsp;the world's most-popular website this year.</li>\n <li>Amazon(NASDAQ:AMZN)was able to claim a title, of sorts, as a new survey from the&nbsp;<i>Washington Post</i>&nbsp;said they felt the e-commerce titan&nbsp;was just a bit more trustworthy than Apple(AAPL).</li>\n <li>As the Omicron variant of the Covid-19 virus continued to spread, Apple (AAPL) closed eight of its North American retail stores&nbsp;due to rises cases among employees. Meanwhile, the state of the upcoming Consumer Electronics Show in Las Vegas began to get cloudy as Amazon (AMZN), Twitter(NYSE:TWTR)and Facebook's Meta Platforms(NASDAQ:FB)pulled out of the in-person part of the tech conference&nbsp;due to concerns about the Covid-19 pandemic.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech Roundup: Micron and 2022 predictions lead Christmas-shortened week's action</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech Roundup: Micron and 2022 predictions lead Christmas-shortened week's action\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 09:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783310-tech-roundup-micron-and-2022-predictions-lead-christmas-shortened-weeks-action><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It may have been a short week for Wall Street due to stock markets being closed on Friday because of the Christmas holiday, but that didn't keep a handful of tech companies from remaining active ...</p>\n\n<a href=\"https://seekingalpha.com/news/3783310-tech-roundup-micron-and-2022-predictions-lead-christmas-shortened-weeks-action\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JD":"京东","MU":"美光科技","BABA":"阿里巴巴"},"source_url":"https://seekingalpha.com/news/3783310-tech-roundup-micron-and-2022-predictions-lead-christmas-shortened-weeks-action","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132092278","content_text":"It may have been a short week for Wall Street due to stock markets being closed on Friday because of the Christmas holiday, but that didn't keep a handful of tech companies from remaining active during what is normally a relatively quiet time of the year.\nMicron Technology(NASDAQ:MU)started things off when, on Monday, it reported strong quarterly results, and gave a business outlook that suggested it is taking steps to alleviate supply chain issues that have impacted the chip sector this year.\nAlong with its upbeat forecast, Micron (MU) got high marks from Rosenblatt Securities analyst Hans Mosesmann, who named Micron (MU)one of his top semiconductor picks for 2022. By the time U.S. stock markets closed Thursday, Micron (MU) shares had climbed 13% for the week.\nOracle(NYSE:ORCL)appeared to be going back to its old-school big-dealing ways when it said it would pay $28.3 billion in cash to buy healthcare technology company Cerner(NASDAQ:CERN)in what stands to be Oracle's (ORCL) largest-ever acquisition.\nChinese tech stocks had their usual bit of drama, as Alibaba(NYSE:BABA)shares bounced up and down after Atlantic Equities downgraded the Internet giant, and JD.com(NASDAQ:JD)slumped at the end of the week after Tencent Holdings(OTCPK:TCEHY)said it would divest most of its holdings in the Chinese e-commerce and retail company.\nAnalysts spent much of the week leading up to Christmas by getting in their takes on what to expect from various tech sectors next year.\nUBS analyst Timothy Arcuri said Nvidia(NASDAQ:NVDA), Micron (MU) and Marvell(NASDAQ:MRVL)were his top selections for investors looking at semiconductor stocks in 2022, while Citi analyst Jim Suva gave five examples of why Apple(NASDAQ:AAPL)shares should continue to rise next yearand lift the company's market value past $3 trillion.\nMeanwhile, MKM Partners managing director pointed out10 examples of \"Black Swan\" eventsthat, while not likely to happen, would have huge impacts on the Internet sector if they did.\nYou know all those kids and everyone else that using and watching videos on TikTok? Well, they have all helped TikTok to surpass Google(NASDAQ:GOOG)as the world's most-popular website this year.\nAmazon(NASDAQ:AMZN)was able to claim a title, of sorts, as a new survey from the Washington Post said they felt the e-commerce titan was just a bit more trustworthy than Apple(AAPL).\nAs the Omicron variant of the Covid-19 virus continued to spread, Apple (AAPL) closed eight of its North American retail stores due to rises cases among employees. Meanwhile, the state of the upcoming Consumer Electronics Show in Las Vegas began to get cloudy as Amazon (AMZN), Twitter(NYSE:TWTR)and Facebook's Meta Platforms(NASDAQ:FB)pulled out of the in-person part of the tech conference due to concerns about the Covid-19 pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698515653,"gmtCreate":1640446861197,"gmtModify":1640446861324,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698515653","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","pubTimestamp":1640398248,"share":"https://www.laohu8.com/m/news/2193917872?lang=&edition=full","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<p>Since Warren Buffett took full control of <b>Berkshire Hathaway</b> in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.</p>\n<p>The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.</p>\n<h2>1. Johnson &amp; Johnson</h2>\n<p>The first pharma stock within Berkshire's portfolio to contemplate purchasing is <b>Johnson &amp; Johnson</b> (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.</p>\n<p>J&amp;J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.</p>\n<p>J&amp;J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&amp;J's $69 billion in net sales.</p>\n<p>These drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.</p>\n<p>J&amp;J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.</p>\n<p>Income investors can scoop up J&amp;J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.</p>\n<h2>2. Bristol Myers Squibb</h2>\n<p>Another Buffett stock that could be a great fit in your portfolio is <b>Bristol Myers Squibb</b> (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.</p>\n<p>Bristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with <b>Pfizer</b> (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.</p>\n<p>What matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.</p>\n<p>As a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.</p>\n<p>Yield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.</p>\n<h2>3. AbbVie</h2>\n<p>Finally, a Buffett stock that'd also be a good fit for income investors is <b>AbbVie</b> (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.</p>\n<p>It's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.</p>\n<p>AbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.</p>\n<p>AbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3.&nbsp;This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","JNJ":"强生","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699256009,"gmtCreate":1639819907809,"gmtModify":1639819907809,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks for info","listText":"Thanks for info","text":"Thanks for info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699256009","repostId":"1109895138","repostType":4,"repost":{"id":"1109895138","pubTimestamp":1639810699,"share":"https://www.laohu8.com/m/news/1109895138?lang=&edition=full","pubTime":"2021-12-18 14:58","market":"us","language":"en","title":"1 Surefire Growth Stock to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1109895138","media":"Motley Fool","summary":"Globant may not be a familiar name to many investors, and at first glance, this company may fail to ","content":"<p><a href=\"https://laohu8.com/S/GLOB\"><b>Globant</b></a>&nbsp;may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this stock is up 380% over the past three years, crushing the&nbsp;<b>S&amp;P 500</b>, and that outperformance could continue in the future.</p>\n<p>Globant employs over 20,500&nbsp;IT professionals with expertise in emerging technologies like artificial intelligence, augmented reality, and the metaverse. To that end, the founder-led management team has positioned Globant as a key enabler of digital transformation, meaning the company benefits from a massive and growing market opportunity.</p>\n<p><b>Trevor Jennewine:</b>&nbsp;Globant comes to mind when I think about companies with great management. Globant was founded by four friends in Latin America in 2003. One of those four people was the current CEO, Martin Migoya.</p>\n<p>Globant specializes in IT consulting and product engineering. The company's expertise spans the gamut of trendy technologies, from blockchain and artificial intelligence to data analytics and augmented reality. In a nutshell, Globant essentially helps organizations achieve their digital transformation initiatives. It has customers like<b>Electronic Arts</b>,<b>MercadoLibre</b>, [<b>Alphabet</b>'s] Google,<b>Walt Disney</b>. This is a big market -- digital transformation is a pretty popular buzzword right now. The company puts its addressable market at $154 billion by 2022.</p>\n<p>Some of those things I mentioned earlier, I like that you have this founder-led management team. If you look at Glassdoor, it appears that there's a strong workplace culture: 93% of people would recommend the company to a friend, 96% of people approve of the CEO. I think that's especially important for a consulting company. Globant's business is built around helping organizations implement and scale new technologies, operate more efficiently, improve the customer experience. That's going to be difficult if your employees don't like coming to work every day.</p>\n<p>Then, the company's has also received some recognition that speak to the success that it's having. Globant is one of the top five fastest-growing engineering services companies based on a report from Everest Group. It's also a leader and customer experience improvement services based on a report from the International Data Corporation.</p>\n<p>The financial results look great here, too. Over the last year, $1.2 billion in revenue up 50%; $2.07 per diluted share on the bottom line, up 64%. They also have over 1,000 customers now. They grew their customer base 14%. But the customers spending over $1 million, they have 162 of those customers now -- that's up 37%. It's nice to see them ramping spend from their customer base there.</p>\n<p>Then between 2022 and 2024, according to the International Data Corporation, enterprises around the world will spend $6.3 trillion on the digital transformation initiatives. This is just a massive market opportunity. I think having that founder CEO there, I think he's really taken the company in a good direction. That gives me a lot of confidence in Globant going forward.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Surefire Growth Stock to Buy and Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Surefire Growth Stock to Buy and Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Globant may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLOB":"Globant"},"source_url":"https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109895138","content_text":"Globant may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this stock is up 380% over the past three years, crushing the S&P 500, and that outperformance could continue in the future.\nGlobant employs over 20,500 IT professionals with expertise in emerging technologies like artificial intelligence, augmented reality, and the metaverse. To that end, the founder-led management team has positioned Globant as a key enabler of digital transformation, meaning the company benefits from a massive and growing market opportunity.\nTrevor Jennewine: Globant comes to mind when I think about companies with great management. Globant was founded by four friends in Latin America in 2003. One of those four people was the current CEO, Martin Migoya.\nGlobant specializes in IT consulting and product engineering. The company's expertise spans the gamut of trendy technologies, from blockchain and artificial intelligence to data analytics and augmented reality. In a nutshell, Globant essentially helps organizations achieve their digital transformation initiatives. It has customers likeElectronic Arts,MercadoLibre, [Alphabet's] Google,Walt Disney. This is a big market -- digital transformation is a pretty popular buzzword right now. The company puts its addressable market at $154 billion by 2022.\nSome of those things I mentioned earlier, I like that you have this founder-led management team. If you look at Glassdoor, it appears that there's a strong workplace culture: 93% of people would recommend the company to a friend, 96% of people approve of the CEO. I think that's especially important for a consulting company. Globant's business is built around helping organizations implement and scale new technologies, operate more efficiently, improve the customer experience. That's going to be difficult if your employees don't like coming to work every day.\nThen, the company's has also received some recognition that speak to the success that it's having. Globant is one of the top five fastest-growing engineering services companies based on a report from Everest Group. It's also a leader and customer experience improvement services based on a report from the International Data Corporation.\nThe financial results look great here, too. Over the last year, $1.2 billion in revenue up 50%; $2.07 per diluted share on the bottom line, up 64%. They also have over 1,000 customers now. They grew their customer base 14%. But the customers spending over $1 million, they have 162 of those customers now -- that's up 37%. It's nice to see them ramping spend from their customer base there.\nThen between 2022 and 2024, according to the International Data Corporation, enterprises around the world will spend $6.3 trillion on the digital transformation initiatives. This is just a massive market opportunity. I think having that founder CEO there, I think he's really taken the company in a good direction. That gives me a lot of confidence in Globant going forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699258408,"gmtCreate":1639819854861,"gmtModify":1639819855010,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699258408","repostId":"2192754259","repostType":4,"repost":{"id":"2192754259","pubTimestamp":1639811460,"share":"https://www.laohu8.com/m/news/2192754259?lang=&edition=full","pubTime":"2021-12-18 15:11","market":"us","language":"en","title":"Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2192754259","media":"Motley Fool","summary":"Three names you know are trading within 10% of their 52-week lows. They deserve better.","content":"<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.</p>\n<p><b>Disney</b>&nbsp;(NYSE:DIS),<b> <a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b>&nbsp;(NYSE:TWTR), and <b>Toast </b>(NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.</p>\n<h4><a href=\"https://laohu8.com/S/DIS\">Disney</a></h4>\n<p>Disney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.</p>\n<p>It's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.</p>\n<p>Disney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.</p>\n<p><b><a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b></p>\n<p>Another shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.</p>\n<p>The platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.</p>\n<h4><a href=\"https://laohu8.com/S/TOST\">Toast</a></h4>\n<p>Running a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.</p>\n<p>Toast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.</p>\n<p>Despite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 15:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4507":"流媒体概念","BK4561":"索罗斯持仓","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4532":"文艺复兴科技持仓","TWTR":"Twitter","BK4554":"元宇宙及AR概念","BK4534":"瑞士信贷持仓","BK4106":"数据处理与外包服务","DIS":"迪士尼","BK4108":"电影和娱乐","BK4551":"寇图资本持仓","BK4524":"宅经济概念","BK4508":"社交媒体","QNETCN":"纳斯达克中美互联网老虎指数","TOST":"Toast, Inc."},"source_url":"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192754259","content_text":"The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.\nDisney (NYSE:DIS), Twitter (NYSE:TWTR), and Toast (NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.\nDisney\nDisney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.\nIt's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.\nDisney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.\nTwitter\nAnother shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.\nThe platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.\nToast\nRunning a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.\nToast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.\nDespite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.","news_type":1},"isVote":1,"tweetType":1,"viewCount":499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698515653,"gmtCreate":1640446861197,"gmtModify":1640446861324,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698515653","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","pubTimestamp":1640398248,"share":"https://www.laohu8.com/m/news/2193917872?lang=&edition=full","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<p>Since Warren Buffett took full control of <b>Berkshire Hathaway</b> in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.</p>\n<p>The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.</p>\n<h2>1. Johnson &amp; Johnson</h2>\n<p>The first pharma stock within Berkshire's portfolio to contemplate purchasing is <b>Johnson &amp; Johnson</b> (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.</p>\n<p>J&amp;J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.</p>\n<p>J&amp;J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&amp;J's $69 billion in net sales.</p>\n<p>These drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.</p>\n<p>J&amp;J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.</p>\n<p>Income investors can scoop up J&amp;J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.</p>\n<h2>2. Bristol Myers Squibb</h2>\n<p>Another Buffett stock that could be a great fit in your portfolio is <b>Bristol Myers Squibb</b> (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.</p>\n<p>Bristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with <b>Pfizer</b> (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.</p>\n<p>What matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.</p>\n<p>As a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.</p>\n<p>Yield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.</p>\n<h2>3. AbbVie</h2>\n<p>Finally, a Buffett stock that'd also be a good fit for income investors is <b>AbbVie</b> (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.</p>\n<p>It's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.</p>\n<p>AbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.</p>\n<p>AbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3.&nbsp;This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","JNJ":"强生","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696723093,"gmtCreate":1640774600324,"gmtModify":1640774600489,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696723093","repostId":"1198370121","repostType":4,"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699258408,"gmtCreate":1639819854861,"gmtModify":1639819855010,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699258408","repostId":"2192754259","repostType":4,"repost":{"id":"2192754259","pubTimestamp":1639811460,"share":"https://www.laohu8.com/m/news/2192754259?lang=&edition=full","pubTime":"2021-12-18 15:11","market":"us","language":"en","title":"Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2192754259","media":"Motley Fool","summary":"Three names you know are trading within 10% of their 52-week lows. They deserve better.","content":"<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.</p>\n<p><b>Disney</b>&nbsp;(NYSE:DIS),<b> <a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b>&nbsp;(NYSE:TWTR), and <b>Toast </b>(NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.</p>\n<h4><a href=\"https://laohu8.com/S/DIS\">Disney</a></h4>\n<p>Disney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.</p>\n<p>It's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.</p>\n<p>Disney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.</p>\n<p><b><a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b></p>\n<p>Another shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.</p>\n<p>The platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.</p>\n<h4><a href=\"https://laohu8.com/S/TOST\">Toast</a></h4>\n<p>Running a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.</p>\n<p>Toast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.</p>\n<p>Despite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 15:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4507":"流媒体概念","BK4561":"索罗斯持仓","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4532":"文艺复兴科技持仓","TWTR":"Twitter","BK4554":"元宇宙及AR概念","BK4534":"瑞士信贷持仓","BK4106":"数据处理与外包服务","DIS":"迪士尼","BK4108":"电影和娱乐","BK4551":"寇图资本持仓","BK4524":"宅经济概念","BK4508":"社交媒体","QNETCN":"纳斯达克中美互联网老虎指数","TOST":"Toast, Inc."},"source_url":"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192754259","content_text":"The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.\nDisney (NYSE:DIS), Twitter (NYSE:TWTR), and Toast (NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.\nDisney\nDisney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.\nIt's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.\nDisney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.\nTwitter\nAnother shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.\nThe platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.\nToast\nRunning a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.\nToast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.\nDespite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.","news_type":1},"isVote":1,"tweetType":1,"viewCount":499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699256009,"gmtCreate":1639819907809,"gmtModify":1639819907809,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks for info","listText":"Thanks for info","text":"Thanks for info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699256009","repostId":"1109895138","repostType":4,"repost":{"id":"1109895138","pubTimestamp":1639810699,"share":"https://www.laohu8.com/m/news/1109895138?lang=&edition=full","pubTime":"2021-12-18 14:58","market":"us","language":"en","title":"1 Surefire Growth Stock to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1109895138","media":"Motley Fool","summary":"Globant may not be a familiar name to many investors, and at first glance, this company may fail to ","content":"<p><a href=\"https://laohu8.com/S/GLOB\"><b>Globant</b></a>&nbsp;may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this stock is up 380% over the past three years, crushing the&nbsp;<b>S&amp;P 500</b>, and that outperformance could continue in the future.</p>\n<p>Globant employs over 20,500&nbsp;IT professionals with expertise in emerging technologies like artificial intelligence, augmented reality, and the metaverse. To that end, the founder-led management team has positioned Globant as a key enabler of digital transformation, meaning the company benefits from a massive and growing market opportunity.</p>\n<p><b>Trevor Jennewine:</b>&nbsp;Globant comes to mind when I think about companies with great management. Globant was founded by four friends in Latin America in 2003. One of those four people was the current CEO, Martin Migoya.</p>\n<p>Globant specializes in IT consulting and product engineering. The company's expertise spans the gamut of trendy technologies, from blockchain and artificial intelligence to data analytics and augmented reality. In a nutshell, Globant essentially helps organizations achieve their digital transformation initiatives. It has customers like<b>Electronic Arts</b>,<b>MercadoLibre</b>, [<b>Alphabet</b>'s] Google,<b>Walt Disney</b>. This is a big market -- digital transformation is a pretty popular buzzword right now. The company puts its addressable market at $154 billion by 2022.</p>\n<p>Some of those things I mentioned earlier, I like that you have this founder-led management team. If you look at Glassdoor, it appears that there's a strong workplace culture: 93% of people would recommend the company to a friend, 96% of people approve of the CEO. I think that's especially important for a consulting company. Globant's business is built around helping organizations implement and scale new technologies, operate more efficiently, improve the customer experience. That's going to be difficult if your employees don't like coming to work every day.</p>\n<p>Then, the company's has also received some recognition that speak to the success that it's having. Globant is one of the top five fastest-growing engineering services companies based on a report from Everest Group. It's also a leader and customer experience improvement services based on a report from the International Data Corporation.</p>\n<p>The financial results look great here, too. Over the last year, $1.2 billion in revenue up 50%; $2.07 per diluted share on the bottom line, up 64%. They also have over 1,000 customers now. They grew their customer base 14%. But the customers spending over $1 million, they have 162 of those customers now -- that's up 37%. It's nice to see them ramping spend from their customer base there.</p>\n<p>Then between 2022 and 2024, according to the International Data Corporation, enterprises around the world will spend $6.3 trillion on the digital transformation initiatives. This is just a massive market opportunity. I think having that founder CEO there, I think he's really taken the company in a good direction. That gives me a lot of confidence in Globant going forward.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Surefire Growth Stock to Buy and Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Surefire Growth Stock to Buy and Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Globant may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLOB":"Globant"},"source_url":"https://www.fool.com/investing/2021/12/17/1-surefire-growth-stock-to-buy-and-hold/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109895138","content_text":"Globant may not be a familiar name to many investors, and at first glance, this company may fail to grab your attention. After all, IT consulting isn't the most groundbreaking business model. But this stock is up 380% over the past three years, crushing the S&P 500, and that outperformance could continue in the future.\nGlobant employs over 20,500 IT professionals with expertise in emerging technologies like artificial intelligence, augmented reality, and the metaverse. To that end, the founder-led management team has positioned Globant as a key enabler of digital transformation, meaning the company benefits from a massive and growing market opportunity.\nTrevor Jennewine: Globant comes to mind when I think about companies with great management. Globant was founded by four friends in Latin America in 2003. One of those four people was the current CEO, Martin Migoya.\nGlobant specializes in IT consulting and product engineering. The company's expertise spans the gamut of trendy technologies, from blockchain and artificial intelligence to data analytics and augmented reality. In a nutshell, Globant essentially helps organizations achieve their digital transformation initiatives. It has customers likeElectronic Arts,MercadoLibre, [Alphabet's] Google,Walt Disney. This is a big market -- digital transformation is a pretty popular buzzword right now. The company puts its addressable market at $154 billion by 2022.\nSome of those things I mentioned earlier, I like that you have this founder-led management team. If you look at Glassdoor, it appears that there's a strong workplace culture: 93% of people would recommend the company to a friend, 96% of people approve of the CEO. I think that's especially important for a consulting company. Globant's business is built around helping organizations implement and scale new technologies, operate more efficiently, improve the customer experience. That's going to be difficult if your employees don't like coming to work every day.\nThen, the company's has also received some recognition that speak to the success that it's having. Globant is one of the top five fastest-growing engineering services companies based on a report from Everest Group. It's also a leader and customer experience improvement services based on a report from the International Data Corporation.\nThe financial results look great here, too. Over the last year, $1.2 billion in revenue up 50%; $2.07 per diluted share on the bottom line, up 64%. They also have over 1,000 customers now. They grew their customer base 14%. But the customers spending over $1 million, they have 162 of those customers now -- that's up 37%. It's nice to see them ramping spend from their customer base there.\nThen between 2022 and 2024, according to the International Data Corporation, enterprises around the world will spend $6.3 trillion on the digital transformation initiatives. This is just a massive market opportunity. I think having that founder CEO there, I think he's really taken the company in a good direction. That gives me a lot of confidence in Globant going forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698487888,"gmtCreate":1640494482107,"gmtModify":1640494482185,"author":{"id":"3579236690659078","authorId":"3579236690659078","name":"JemP","avatar":"https://static.tigerbbs.com/cc9231e18ef20b53bdfefe5eba40161c","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698487888","repostId":"1132092278","repostType":4,"isVote":1,"tweetType":1,"viewCount":635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}